SlideShare a Scribd company logo
HYPERTENSION IN ELDERY
PRESENTED BY--
DR MANINDERPAL SINGH
Junior Resident 1
GEN MEDICINE
DEFINATION
• Hypertension is defined as the presence of a
blood pressure elevation to a level that places
patients at increased risk for target organ
damage in several vascular beds including the
retina, brain , heart, kidneys and large conduit
arteries .
BLOOD PRESSURE CLASSIFICATIONS IN ADULTS
BLOOD PRESSURE
CATEGORY
SYSTOLIC (MMHG) DIASTOLIC (MMHG )
NORMAL <120 and <80
ELEVATED 120-129 And <80
HYPERTENSION
STAGE 1 130-139 OR 80-89
STAGE 2 >=140 OR >90
SOURCE , 2017 ACC/ AHA
• There is a dramatic increase in the
prevalence of hypertension with
aging ; by age 70 years, the majority
of people have hypertension .
EPIDEMIOLGY OF HYPERTENSION AND
AGING
• Without treatment , approximately 40% of adults
have hypertension
• HTN prevalence increases markedly with age
a) By 60 years ~ 65 % have HTN
b) By 70 years ~ 90 % have HTN ( ISH)
• In Framingham Study , HTN eventually developed in >
90% of people with normal BP at age of 55 years .
Recent NHANES findings
• In older adults , hypertension is
characterised by an elevated systolic
blood pressure with normal or low
diastolic BP , due to age associated
stiffening of the large arteries .
JOINT INFLUENCES OF SBP AND PULSE
PRESSURE ON CORONARY HEART DISEASE
Thus pulse pressure is the most important predictor of cardiovascular risk in the
elderly
PATHOPHYSIOLOGY OF HYPERTENSION IN THE
ELDERLY
• Multiple changes occur in arterial media with
aging , including reduced elastin content with
increase in non distensible collagen and calcium (
eg arterial stiffening )
• Age associated arterial stiffening results in a
gradual increase in systolic BP and a decrease in
diastolic BP
• Flow – mediated arterial dilation , primarily
mediated by endothelium derived nitric oxide,
declines markedly with aging
PATHOPHYSIOLOGY CONTINUES
 The changes in the vessel wall results in increased
pulse wave velocity , early return of reflected waves
from the periphery and altered contour of the pulse
waveform .
 The net effect is an elevated SBP and augmentation
index .
 DBP is also reduced due to reduced elastic recoil of stiff
arteries .
 The changes in SBP and DBP are clearly responsible for
the increased afterload , wall tension of the left
ventricle, reduced coronary perfusion pressure ,
diastolic dysfunction and left atrial enlargement
PATHOPHYSIOLOGY CONTINUES………
• Neurohormonal profile of older hypertensive
adults characterized by increased plasma
norepinephrine , low renin , and low
aldosterone levels
• Many so called normal aging changes in
arterial structures and function are blunted /
absent in population not chronically exposed
to high sodium/high calorie diets, low physical
activity levels , and high rates of obesity
Hypertension as a Risk Factor in the
Elderly
• In older adults , Hypertension is the most
prevalent modifiable CV risk factor: antecedent
HTN is estimated in :
 ~ 70 % of patients with incident myocardial
infarction
 ~ 77 % of patients with incident strokes
 ~ 74 % with chronic Heart Failure
 ~ 90 % with acute aortic syndrome
 ~ 30 % to 40 % with atrial fibrillation
Hypertension continues….
• HTN is also a major risk factor for conditions
directly influencing CV risk in the elderly
a) Diabetes
b) Metabolic Syndrome
c) Chronic kidney disease
Failure to control BP with combination of 3 or
more drugs including diuretics with adequate
dose and duration
• Unsuspected secondary cause
• Poor adherance to therapeutic plan
• Failure to modify lifestyle
• Volume overload – inadequate diuretic therapy,
progressive renal failure, high sodium intake
• Whitecoat hypertension
• Small cuff on large arm
• Too early measure after nicotine or caffiene intake
Refractory Hypertension
Reason ?
Hypertensive crisis
• Hypertensive emergency – critical elevation of blood
pressure (SBP >=140mmhg & DBP >=90 mmhg) associated
with features of acute or ongoing TOD as evident clinically
or by laboratory findings( Acute LVF, ARF,Encepahopathy )
• Hypertensive urgency – DBP >= 120mmhg & No features
of TOD
• Accelerated hypertension- High BP (SBP>= 140mmhg &
DBP >= 90mmhg ) with vascular damage ( retinal
hemorrhages & Exudates )
• Malignant hypertension – High BP ( SBP>=140 mmhg &
DBP >=90MMHG) with features of papilledema
Steps in clinical evaluation of
hypertension
• Duration and severity of elevated BP
• History of prior medications and antihypertenssive
medication use
• Use of tobacco , alcohol
• Risk factors for CAD
• Family history of hypertension, Diabetes, CVD
• Psychosocial history ( presence of stress, insomnia )
• Dietary habbits, physical activity and weight changes in
the recent past
• Features of TOD
Some features suggestive of secondary
HTN should be specially looked for
• Abrupt onset of hypertension
• Sudden worsening of previously well
controlled BP
• Refractory hypertension
• Episodes of hypertensive criris
• Specific symptoms and signs related to the
cause of HTN ( eg , azotemia in renal
parenchymal disease )
Extent of Awareness, Treatment and Control of
High Blood Pressure by Age
BP Control Rates remain suboptimal in the elderly
Routine Tests recommended for the
initial evaluation of a hypertensive
patient
• Serum chemistry
• glucose
• potassium
• creatinine
• sodium
• Serum Total and HDL Cholesterol
• Urinalysis
• Electrocardiogram , CBC
Other investigations
• Chest radiography – cardiomegaly, heart failure, CoA
• Ambulatory BP recording – to assess border line or
whitecoat HTN
• Echocardiogram – to detect or quantify LVH
• Renal ultrasound – to detect possible renal disease
• Renal angiography – to detect or confirm presence of
renal artery stenosis
• Urinary cortisol and dexamethasone suppression test – to
detect possible Cushing’s syndrome
• Plasma renin activity and aldosterone – to detect
possible primary aldosteronism
Lifestyle modifications that lower blood pressure
Primary lifestyle modification
 Reduction of body weight (10 kg reduces BP ~ 10/8 mmHg)
 Reduction in dietary salt consumption ( target 100 mmol/day, can
lower BP ~ 12/10 mmHg, but individual responses vary)
 Increase physical activity to 30 – 45 mins, 4 times a week ( can lower
BP 8/4 mmHg and often helps control weight)
 Increase consumption of fruits and vegetables (at least 4
servings/day, can lower BP 6/3 mmHg and often helps reduce salt
consumption)
 Moderation of alcohol consumption (target 10 -20 g ethanol for
women, 20 – 30 g for men, can lower BP up to 8/4 mmHg in those
who have more than 5 drinks/ day)
 Stress management (randomized clinical trials outside the workplace
have been unconvincing, but many psychologists still recommend
the approach despite a lack of detailed protocols that uniformely
lower BP)
Other lifestyle modifications that are routinely
recommended
• Tobacco avoidance (lowers cardiovascular risk
independently of any effect on BP)
• Fish consumption (improves lipid profiles and
cardiovascular risk more than expected if BP effects alone is
operative)
• Increasing dietary fibre (improves lipid profiles and cancer
risk independently of effect on BP)
• DASH (Dietry Approach to Stop Hypertension) Diet:-
• Potassium Rich fruits, Low salt and total fat, Increased
vegetable and fruits, and low Dairy Products.
Randomized Hypertension in the Very
Elderly Trail ( HYVET )
• In 3845 patients , > 80 years old with SBP>= 160
MMHG, AT 1.8 Year follow up, those randomized
to indapamide vs placebo had :
a) 30% non significant decrease in fatal/nonfatal
stroke
b) 39% significant decrease in fatal stroke
c) 21% significant decrease in all cause mortality
d) 23 % insignificant decrease in CV death
e) 64% significant decrease in heart failure
Pharmacological Management
It is based on the same principles as for younger
people with minor differences -
• The elderly have reduced body mass, reduced liver
and kidney mass. Absorption capacity is reduced
hence the pharmacokinetics of drugs are altered
• Some of the drugs commonly prescribed in the
elderly increases BP and interfere with
antihypertensive therapy. These are
corticosteroids, anabolic steroids, NSAIDS, and
erythropoietin
• All the drug classes have similar BP lowering
efficacy and CV risk reduction is largely due to BP
lowering and not due to any individual drug effect .
• If there are no compelling indications , start with a low
dose of any drug ( preferably a thiazide type diuretic ) .
Add a second drug if Goal BP is not achieved inspite of
maximally tolerated dose. Similarly , add a third drug
and assess for secondary hypertension if desired
response in not obtained .
• Thiazide type diuretics and dihydropyridine CCBs are
the most studied drugs in the geriatric population.
• In the presence of compelling indications, start with
drug class shown to have maximal benefit .
• Check regularly for compliance , postural hypotension
and side effects of drugs .
Key Message
1. Aging is associated with increased stiffness of vessels and
very high prevalence of hypertension. The prevalence is
also influneced by dietary factors( salt intake ) and other
poorly understood influences( hormonal influences )
2. All forms of hypertension are common in the elderly ;
though ISH is the commonest
3. There are no clear guidelines on different risk profile older
people, practical defination of hyperetnsion and goal BP
to be achived . Currently , 140/90mmhg is the diagnostic
threshold and also the goal BP for people in the age group
of 60-79 years of age . For octogenarians and beyond,
based on the data available, a diagnostic threshold of
160mmhg seems reasonable and a goal BP in the range of
140-145 mmhg is a reasonable target if tolerated well .
4 In older people , there is no data to support the
lower BP targets in the presence of DIABETES ,
CKD &CVD
5 There is a need to identify which drugs are most
suitable and well tolerated by the elderly and
also most effective in reducing CV risk
6 Drug compliance is poor in this group because of
cost, cognitive impairment , multiple drug intake
for co-morbidities etc . Emphasis should be on
using low cost combinations
7 Fundamental research should focus on
understanding the pathophysiology of
vascular stiffness to develop methods to
reverse and prevent it
8 There is a need to generate data on local
populations, specially in our country , in
different age sections within the elderly and
with different co-morbidities
THANK YOU

More Related Content

What's hot

Hypertension management 2018
Hypertension management  2018Hypertension management  2018
Hypertension management 2018
Monkez M Yousif
 
ESC/ESH 2018
ESC/ESH 2018ESC/ESH 2018
ESC/ESH 2018
desktoppc
 
Hypertension
HypertensionHypertension
Hypertension
Ramachandra Barik
 
BP VARIABILITY
BP VARIABILITYBP VARIABILITY
BP VARIABILITY
Praveen Nagula
 
DYSLIPIDEMIA 2022.ppt
DYSLIPIDEMIA 2022.pptDYSLIPIDEMIA 2022.ppt
DYSLIPIDEMIA 2022.ppt
JosephRepotente
 
Hypertension
HypertensionHypertension
Management of dyslipidemia 2019 update
Management of dyslipidemia  2019 update Management of dyslipidemia  2019 update
Management of dyslipidemia 2019 update
Moustafa Mokarrab
 
Management of hypertension in diabetes
Management of hypertension in diabetesManagement of hypertension in diabetes
Management of hypertension in diabetes
mondy19
 
What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“
Arindam Pande
 
Evaluation and management of hypertension
Evaluation and management of hypertensionEvaluation and management of hypertension
Evaluation and management of hypertension
Nagesh Waghmare
 
Management of dyslipidemia
Management of dyslipidemiaManagement of dyslipidemia
Management of dyslipidemia
Rajesh Rayidi
 
Ramadan and cvd
Ramadan and cvdRamadan and cvd
Ramadan and cvd
FarragBahbah
 
Trajectories of lipids profile and incident cvd risk
Trajectories of lipids profile and incident cvd riskTrajectories of lipids profile and incident cvd risk
Trajectories of lipids profile and incident cvd risk
Praveen Nagula
 
Hypertension 2020 Updated Guidelines
Hypertension 2020 Updated GuidelinesHypertension 2020 Updated Guidelines
Hypertension 2020 Updated Guidelines
Dr. Aryan (Anish Dhakal)
 
Device therapy for heart failure monitoring and management
Device therapy for heart failure monitoring  and managementDevice therapy for heart failure monitoring  and management
Device therapy for heart failure monitoring and management
DIPAK PATADE
 
2019 ESC/EAS Guidelines on Dyslipidaemias
2019 ESC/EAS Guidelines on Dyslipidaemias2019 ESC/EAS Guidelines on Dyslipidaemias
2019 ESC/EAS Guidelines on Dyslipidaemias
Sociedad Española de Cardiología
 
Telsarta-A final-01-04-16
Telsarta-A  final-01-04-16Telsarta-A  final-01-04-16
Telsarta-A final-01-04-16
Muhammad Aun
 
Hypertension (HTN)
Hypertension (HTN)Hypertension (HTN)
Hypertension (HTN)
mahadev deuja
 
Evaluation & management of dyslipidemia
Evaluation & management of dyslipidemia Evaluation & management of dyslipidemia
Evaluation & management of dyslipidemia
Mohsen Eledrisi
 
Sprint trial
Sprint trialSprint trial
Sprint trial
Iqbal Dar
 

What's hot (20)

Hypertension management 2018
Hypertension management  2018Hypertension management  2018
Hypertension management 2018
 
ESC/ESH 2018
ESC/ESH 2018ESC/ESH 2018
ESC/ESH 2018
 
Hypertension
HypertensionHypertension
Hypertension
 
BP VARIABILITY
BP VARIABILITYBP VARIABILITY
BP VARIABILITY
 
DYSLIPIDEMIA 2022.ppt
DYSLIPIDEMIA 2022.pptDYSLIPIDEMIA 2022.ppt
DYSLIPIDEMIA 2022.ppt
 
Hypertension
HypertensionHypertension
Hypertension
 
Management of dyslipidemia 2019 update
Management of dyslipidemia  2019 update Management of dyslipidemia  2019 update
Management of dyslipidemia 2019 update
 
Management of hypertension in diabetes
Management of hypertension in diabetesManagement of hypertension in diabetes
Management of hypertension in diabetes
 
What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“What’s new in Lipidology, Lessons from “recent guidelines“
What’s new in Lipidology, Lessons from “recent guidelines“
 
Evaluation and management of hypertension
Evaluation and management of hypertensionEvaluation and management of hypertension
Evaluation and management of hypertension
 
Management of dyslipidemia
Management of dyslipidemiaManagement of dyslipidemia
Management of dyslipidemia
 
Ramadan and cvd
Ramadan and cvdRamadan and cvd
Ramadan and cvd
 
Trajectories of lipids profile and incident cvd risk
Trajectories of lipids profile and incident cvd riskTrajectories of lipids profile and incident cvd risk
Trajectories of lipids profile and incident cvd risk
 
Hypertension 2020 Updated Guidelines
Hypertension 2020 Updated GuidelinesHypertension 2020 Updated Guidelines
Hypertension 2020 Updated Guidelines
 
Device therapy for heart failure monitoring and management
Device therapy for heart failure monitoring  and managementDevice therapy for heart failure monitoring  and management
Device therapy for heart failure monitoring and management
 
2019 ESC/EAS Guidelines on Dyslipidaemias
2019 ESC/EAS Guidelines on Dyslipidaemias2019 ESC/EAS Guidelines on Dyslipidaemias
2019 ESC/EAS Guidelines on Dyslipidaemias
 
Telsarta-A final-01-04-16
Telsarta-A  final-01-04-16Telsarta-A  final-01-04-16
Telsarta-A final-01-04-16
 
Hypertension (HTN)
Hypertension (HTN)Hypertension (HTN)
Hypertension (HTN)
 
Evaluation & management of dyslipidemia
Evaluation & management of dyslipidemia Evaluation & management of dyslipidemia
Evaluation & management of dyslipidemia
 
Sprint trial
Sprint trialSprint trial
Sprint trial
 

Similar to HYPERTENSION IN ELDERY 2023.pptx

Hypertension 2012
Hypertension 2012Hypertension 2012
Hypertension 2012
Uday Prashant
 
Approach to a patient with resistant hypertension
Approach to a patient with resistant hypertensionApproach to a patient with resistant hypertension
Approach to a patient with resistant hypertension
PROFESSOR DR. MD. TOUFIQUR RAHMAN
 
HYPERTENSIVE NEPHROPATHY.pptx
HYPERTENSIVE NEPHROPATHY.pptxHYPERTENSIVE NEPHROPATHY.pptx
HYPERTENSIVE NEPHROPATHY.pptx
MariaMahamed
 
Hypertension (HTN) - High Blood Pressure
Hypertension (HTN) - High Blood PressureHypertension (HTN) - High Blood Pressure
Hypertension (HTN) - High Blood Pressure
Md.Mahmudul Hasan Babor
 
Hypertension
HypertensionHypertension
Hypertension
HypertensionHypertension
Hypertension
Jyoti Sharma
 
Hypertension - Nutrition In Disease
Hypertension - Nutrition In DiseaseHypertension - Nutrition In Disease
Hypertension - Nutrition In Disease
RANJANI GUNASEKARAN
 
hypertension demonstration pharmacology.pptx
hypertension demonstration  pharmacology.pptxhypertension demonstration  pharmacology.pptx
hypertension demonstration pharmacology.pptx
ShabanSaad1
 
htnppt-191211113109(1).pdf
htnppt-191211113109(1).pdfhtnppt-191211113109(1).pdf
htnppt-191211113109(1).pdf
mesh12
 
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
O. E.Nyandi PhD
 
Hypertension guidelines
Hypertension guidelinesHypertension guidelines
Hypertension guidelines
Sachin Shende
 
Hypertension by Dr. Mohib Ali
Hypertension by Dr. Mohib AliHypertension by Dr. Mohib Ali
Hypertension by Dr. Mohib Ali
Mohib Ali
 
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
O. E.Nyandi PhD
 
Hypertension
HypertensionHypertension
Hypertension
ashafernandes4
 
Pharmacotherapy for hypertension
Pharmacotherapy for hypertension Pharmacotherapy for hypertension
Pharmacotherapy for hypertension
Koppala RVS Chaitanya
 
Guidelines for treatment of hypertension
Guidelines for treatment of  hypertensionGuidelines for treatment of  hypertension
Guidelines for treatment of hypertension
Sanjay S
 
Hypertension
HypertensionHypertension
Hypertension
Bhavesh Patel
 
About Hypertension & it's management
About Hypertension & it's managementAbout Hypertension & it's management
About Hypertension & it's management
Marjanul Alam
 
World Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 pptWorld Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 ppt
desktoppc
 
Hypertension
Hypertension Hypertension
Hypertension
fosterford
 

Similar to HYPERTENSION IN ELDERY 2023.pptx (20)

Hypertension 2012
Hypertension 2012Hypertension 2012
Hypertension 2012
 
Approach to a patient with resistant hypertension
Approach to a patient with resistant hypertensionApproach to a patient with resistant hypertension
Approach to a patient with resistant hypertension
 
HYPERTENSIVE NEPHROPATHY.pptx
HYPERTENSIVE NEPHROPATHY.pptxHYPERTENSIVE NEPHROPATHY.pptx
HYPERTENSIVE NEPHROPATHY.pptx
 
Hypertension (HTN) - High Blood Pressure
Hypertension (HTN) - High Blood PressureHypertension (HTN) - High Blood Pressure
Hypertension (HTN) - High Blood Pressure
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension - Nutrition In Disease
Hypertension - Nutrition In DiseaseHypertension - Nutrition In Disease
Hypertension - Nutrition In Disease
 
hypertension demonstration pharmacology.pptx
hypertension demonstration  pharmacology.pptxhypertension demonstration  pharmacology.pptx
hypertension demonstration pharmacology.pptx
 
htnppt-191211113109(1).pdf
htnppt-191211113109(1).pdfhtnppt-191211113109(1).pdf
htnppt-191211113109(1).pdf
 
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
 
Hypertension guidelines
Hypertension guidelinesHypertension guidelines
Hypertension guidelines
 
Hypertension by Dr. Mohib Ali
Hypertension by Dr. Mohib AliHypertension by Dr. Mohib Ali
Hypertension by Dr. Mohib Ali
 
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
Management of Hypertension in Diabetic Patients with Chronic Kidney Disease: ...
 
Hypertension
HypertensionHypertension
Hypertension
 
Pharmacotherapy for hypertension
Pharmacotherapy for hypertension Pharmacotherapy for hypertension
Pharmacotherapy for hypertension
 
Guidelines for treatment of hypertension
Guidelines for treatment of  hypertensionGuidelines for treatment of  hypertension
Guidelines for treatment of hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
About Hypertension & it's management
About Hypertension & it's managementAbout Hypertension & it's management
About Hypertension & it's management
 
World Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 pptWorld Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 ppt
 
Hypertension
Hypertension Hypertension
Hypertension
 

Recently uploaded

Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treatHistopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
DIVYANSHU740006
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
suvadeepdas911
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Oleg Kshivets
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
AyeshaZaid1
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
bkling
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Identifying Major Symptoms of Slip Disc.
 Identifying Major Symptoms of Slip Disc. Identifying Major Symptoms of Slip Disc.
Identifying Major Symptoms of Slip Disc.
Gokuldas Hospital
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
SwisschemDerma
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
Dr. Jyothirmai Paindla
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
19various
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
rishi2789
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...
Donc Test
 

Recently uploaded (20)

Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treatHistopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
 
Aortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 BernAortic Association CBL Pilot April 19 – 20 Bern
Aortic Association CBL Pilot April 19 – 20 Bern
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
 
Histololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptxHistololgy of Female Reproductive System.pptx
Histololgy of Female Reproductive System.pptx
 
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
 
Identifying Major Symptoms of Slip Disc.
 Identifying Major Symptoms of Slip Disc. Identifying Major Symptoms of Slip Disc.
Identifying Major Symptoms of Slip Disc.
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
 
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdfCHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
 
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...
TEST BANK For Community and Public Health Nursing: Evidence for Practice, 3rd...
 

HYPERTENSION IN ELDERY 2023.pptx

  • 1. HYPERTENSION IN ELDERY PRESENTED BY-- DR MANINDERPAL SINGH Junior Resident 1 GEN MEDICINE
  • 2. DEFINATION • Hypertension is defined as the presence of a blood pressure elevation to a level that places patients at increased risk for target organ damage in several vascular beds including the retina, brain , heart, kidneys and large conduit arteries .
  • 3. BLOOD PRESSURE CLASSIFICATIONS IN ADULTS BLOOD PRESSURE CATEGORY SYSTOLIC (MMHG) DIASTOLIC (MMHG ) NORMAL <120 and <80 ELEVATED 120-129 And <80 HYPERTENSION STAGE 1 130-139 OR 80-89 STAGE 2 >=140 OR >90 SOURCE , 2017 ACC/ AHA
  • 4. • There is a dramatic increase in the prevalence of hypertension with aging ; by age 70 years, the majority of people have hypertension .
  • 5. EPIDEMIOLGY OF HYPERTENSION AND AGING • Without treatment , approximately 40% of adults have hypertension • HTN prevalence increases markedly with age a) By 60 years ~ 65 % have HTN b) By 70 years ~ 90 % have HTN ( ISH) • In Framingham Study , HTN eventually developed in > 90% of people with normal BP at age of 55 years .
  • 7.
  • 8. • In older adults , hypertension is characterised by an elevated systolic blood pressure with normal or low diastolic BP , due to age associated stiffening of the large arteries .
  • 9. JOINT INFLUENCES OF SBP AND PULSE PRESSURE ON CORONARY HEART DISEASE Thus pulse pressure is the most important predictor of cardiovascular risk in the elderly
  • 10. PATHOPHYSIOLOGY OF HYPERTENSION IN THE ELDERLY • Multiple changes occur in arterial media with aging , including reduced elastin content with increase in non distensible collagen and calcium ( eg arterial stiffening ) • Age associated arterial stiffening results in a gradual increase in systolic BP and a decrease in diastolic BP • Flow – mediated arterial dilation , primarily mediated by endothelium derived nitric oxide, declines markedly with aging
  • 11. PATHOPHYSIOLOGY CONTINUES  The changes in the vessel wall results in increased pulse wave velocity , early return of reflected waves from the periphery and altered contour of the pulse waveform .  The net effect is an elevated SBP and augmentation index .  DBP is also reduced due to reduced elastic recoil of stiff arteries .  The changes in SBP and DBP are clearly responsible for the increased afterload , wall tension of the left ventricle, reduced coronary perfusion pressure , diastolic dysfunction and left atrial enlargement
  • 12. PATHOPHYSIOLOGY CONTINUES……… • Neurohormonal profile of older hypertensive adults characterized by increased plasma norepinephrine , low renin , and low aldosterone levels • Many so called normal aging changes in arterial structures and function are blunted / absent in population not chronically exposed to high sodium/high calorie diets, low physical activity levels , and high rates of obesity
  • 13. Hypertension as a Risk Factor in the Elderly • In older adults , Hypertension is the most prevalent modifiable CV risk factor: antecedent HTN is estimated in :  ~ 70 % of patients with incident myocardial infarction  ~ 77 % of patients with incident strokes  ~ 74 % with chronic Heart Failure  ~ 90 % with acute aortic syndrome  ~ 30 % to 40 % with atrial fibrillation
  • 14. Hypertension continues…. • HTN is also a major risk factor for conditions directly influencing CV risk in the elderly a) Diabetes b) Metabolic Syndrome c) Chronic kidney disease
  • 15. Failure to control BP with combination of 3 or more drugs including diuretics with adequate dose and duration • Unsuspected secondary cause • Poor adherance to therapeutic plan • Failure to modify lifestyle • Volume overload – inadequate diuretic therapy, progressive renal failure, high sodium intake • Whitecoat hypertension • Small cuff on large arm • Too early measure after nicotine or caffiene intake Refractory Hypertension Reason ?
  • 16. Hypertensive crisis • Hypertensive emergency – critical elevation of blood pressure (SBP >=140mmhg & DBP >=90 mmhg) associated with features of acute or ongoing TOD as evident clinically or by laboratory findings( Acute LVF, ARF,Encepahopathy ) • Hypertensive urgency – DBP >= 120mmhg & No features of TOD • Accelerated hypertension- High BP (SBP>= 140mmhg & DBP >= 90mmhg ) with vascular damage ( retinal hemorrhages & Exudates ) • Malignant hypertension – High BP ( SBP>=140 mmhg & DBP >=90MMHG) with features of papilledema
  • 17. Steps in clinical evaluation of hypertension • Duration and severity of elevated BP • History of prior medications and antihypertenssive medication use • Use of tobacco , alcohol • Risk factors for CAD • Family history of hypertension, Diabetes, CVD • Psychosocial history ( presence of stress, insomnia ) • Dietary habbits, physical activity and weight changes in the recent past • Features of TOD
  • 18. Some features suggestive of secondary HTN should be specially looked for • Abrupt onset of hypertension • Sudden worsening of previously well controlled BP • Refractory hypertension • Episodes of hypertensive criris • Specific symptoms and signs related to the cause of HTN ( eg , azotemia in renal parenchymal disease )
  • 19. Extent of Awareness, Treatment and Control of High Blood Pressure by Age BP Control Rates remain suboptimal in the elderly
  • 20. Routine Tests recommended for the initial evaluation of a hypertensive patient • Serum chemistry • glucose • potassium • creatinine • sodium • Serum Total and HDL Cholesterol • Urinalysis • Electrocardiogram , CBC
  • 21. Other investigations • Chest radiography – cardiomegaly, heart failure, CoA • Ambulatory BP recording – to assess border line or whitecoat HTN • Echocardiogram – to detect or quantify LVH • Renal ultrasound – to detect possible renal disease • Renal angiography – to detect or confirm presence of renal artery stenosis • Urinary cortisol and dexamethasone suppression test – to detect possible Cushing’s syndrome • Plasma renin activity and aldosterone – to detect possible primary aldosteronism
  • 22. Lifestyle modifications that lower blood pressure Primary lifestyle modification  Reduction of body weight (10 kg reduces BP ~ 10/8 mmHg)  Reduction in dietary salt consumption ( target 100 mmol/day, can lower BP ~ 12/10 mmHg, but individual responses vary)  Increase physical activity to 30 – 45 mins, 4 times a week ( can lower BP 8/4 mmHg and often helps control weight)  Increase consumption of fruits and vegetables (at least 4 servings/day, can lower BP 6/3 mmHg and often helps reduce salt consumption)  Moderation of alcohol consumption (target 10 -20 g ethanol for women, 20 – 30 g for men, can lower BP up to 8/4 mmHg in those who have more than 5 drinks/ day)  Stress management (randomized clinical trials outside the workplace have been unconvincing, but many psychologists still recommend the approach despite a lack of detailed protocols that uniformely lower BP)
  • 23. Other lifestyle modifications that are routinely recommended • Tobacco avoidance (lowers cardiovascular risk independently of any effect on BP) • Fish consumption (improves lipid profiles and cardiovascular risk more than expected if BP effects alone is operative) • Increasing dietary fibre (improves lipid profiles and cancer risk independently of effect on BP) • DASH (Dietry Approach to Stop Hypertension) Diet:- • Potassium Rich fruits, Low salt and total fat, Increased vegetable and fruits, and low Dairy Products.
  • 24. Randomized Hypertension in the Very Elderly Trail ( HYVET ) • In 3845 patients , > 80 years old with SBP>= 160 MMHG, AT 1.8 Year follow up, those randomized to indapamide vs placebo had : a) 30% non significant decrease in fatal/nonfatal stroke b) 39% significant decrease in fatal stroke c) 21% significant decrease in all cause mortality d) 23 % insignificant decrease in CV death e) 64% significant decrease in heart failure
  • 25. Pharmacological Management It is based on the same principles as for younger people with minor differences - • The elderly have reduced body mass, reduced liver and kidney mass. Absorption capacity is reduced hence the pharmacokinetics of drugs are altered • Some of the drugs commonly prescribed in the elderly increases BP and interfere with antihypertensive therapy. These are corticosteroids, anabolic steroids, NSAIDS, and erythropoietin • All the drug classes have similar BP lowering efficacy and CV risk reduction is largely due to BP lowering and not due to any individual drug effect .
  • 26. • If there are no compelling indications , start with a low dose of any drug ( preferably a thiazide type diuretic ) . Add a second drug if Goal BP is not achieved inspite of maximally tolerated dose. Similarly , add a third drug and assess for secondary hypertension if desired response in not obtained . • Thiazide type diuretics and dihydropyridine CCBs are the most studied drugs in the geriatric population. • In the presence of compelling indications, start with drug class shown to have maximal benefit . • Check regularly for compliance , postural hypotension and side effects of drugs .
  • 27. Key Message 1. Aging is associated with increased stiffness of vessels and very high prevalence of hypertension. The prevalence is also influneced by dietary factors( salt intake ) and other poorly understood influences( hormonal influences ) 2. All forms of hypertension are common in the elderly ; though ISH is the commonest 3. There are no clear guidelines on different risk profile older people, practical defination of hyperetnsion and goal BP to be achived . Currently , 140/90mmhg is the diagnostic threshold and also the goal BP for people in the age group of 60-79 years of age . For octogenarians and beyond, based on the data available, a diagnostic threshold of 160mmhg seems reasonable and a goal BP in the range of 140-145 mmhg is a reasonable target if tolerated well .
  • 28. 4 In older people , there is no data to support the lower BP targets in the presence of DIABETES , CKD &CVD 5 There is a need to identify which drugs are most suitable and well tolerated by the elderly and also most effective in reducing CV risk 6 Drug compliance is poor in this group because of cost, cognitive impairment , multiple drug intake for co-morbidities etc . Emphasis should be on using low cost combinations
  • 29. 7 Fundamental research should focus on understanding the pathophysiology of vascular stiffness to develop methods to reverse and prevent it 8 There is a need to generate data on local populations, specially in our country , in different age sections within the elderly and with different co-morbidities